What is the role of public education and stem cell tourism? What type of education is available to patients, caregivers and the public? Can public education actually change people’s minds such that they won’t undergo an unproven stem cell-based intervention (SCBI)? These are the questions I will discuss here. But first, let’s just give a […]
Stem Cell Tourism and Patient Education Read More »
I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting? Garr: Neuralstem is moving on all cylinders these days on
Interview with Neuralstem CEO Richard Garr Read More »
Below is a list of upcoming stem cell and regenerative medicine conferences and meetings in 2015. If you do not see your meeting, please let me know and I will include it. This list is meant to be as inclusive as possible, but by listing specific events I am not necessarily endorsing them. Enjoy! January
Stem Cell Meetings & Conferences 2015 Read More »
Guest post on Research Misconduct. By Zubin Master Scientist Yoshiki Sasai, age 52, committed suicide and was found dead on August 5, 2014. Sasai was deputy director of the Center for Developmental Biology (CDB) at RIKEN in Kobe, Japan, and coauthor on two recently retracted Nature papers about a reportedly easier way to make induced
StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought
Interview with StemCells Inc. leadership on hot topics Read More »
The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung
Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »
This is Part 2 of my interview with ALS and stem cell advocate, Ted Harada. You can read Part 1 of my talk with Ted on where things stand today with ALS, the FDA, and the Ice Bucket Challenge. What’s your opinion of the “Right To Try” law in Colorado and the concept more generally?
Interview with Ted Harada Part 2: Right To Try, Neuralstem, and How He’s Doing Read More »
What are the most interesting questions for the stem cell field in 2014 right now? What’s on your mind? I’m not going to give this deep thought, but rather just list those questions bouncing around at the moment in no particular order. You can see a lot of translational/clinical things are on my mind. I’ve
Key questions for stem cell field bouncing around on a Friday morning Read More »
Ted Harada is a wonderful patient advocate for the stem cell field and for the development of safe and effective stem cell products to treat ALS. Ted has ALS and received stem cell-based treatments for it with surprising, very encouraging results. The Harada family is pictured at left with Ted, his wife Michelle as well as
Ted Harada Interview Part 1: Stem Cells for ALS, More Read More »
What the heck happened to the FDA when it comes to regulating stem cell clinics? Has it given up? Or does it just seem that way because it moves in slow motion? The FDA might as well have thrown in the towel because, as I like to say, the stem cell field moves in dog years.
Has the FDA given up on regulating stem cell clinics? Read More »